AbbVie Spends $10.9B on a Drug That Might Not Work

AbbVie is paying $10.9 billion to buy a company developing a new skin treatment still being tested—a bet that it will replace revenue lost to cheaper copy-cat drugs. The cost will dent profits this year, but the company decided future growth matters more than protecting today's earnings.